218亿砸下去 这个赛道目前走到C轮的公司只有5家

This article provides a full overview of financing in China's synthetic biology track dating back to 2015, with key takeaways below:

1. Core baseline data: To date, the track has accumulated 21.8 billion yuan in total financing, with 110 domestic companies securing 301 financing rounds. Only 5 of these companies have reached the Series C stage or beyond, and nearly 80% of all financing events occurred at Series A or earlier, indicating the industry as a whole remains in an early stage. The global synthetic biology market boasts a compound annual growth rate (CAGR) exceeding 21%, and China's market size is projected to reach approximately 142 billion yuan by 2025, leaving abundant room for long-term growth.

2. Industry development trends: Capital inflows surged in 2021, peaked in 2022, and entered a contraction phase from 2023 to 2024, with a clear recovery emerging in 2025. Capital allocation has shifted from concentrated bets on platform companies to a more diversified distribution across segments. The food and alternative protein segment has emerged as a standout growth area, state-owned capital has begun systematic entry into the space, and the integration of AI and synthetic biology is shortening R&D cycles.

3. Core current industry characteristics: The sector has shifted from an earlier period of concept hype to a validation phase, where companies are now required to deliver mass production and commercialization results. Storytelling alone is no longer sufficient to secure follow-on financing, and the industry as a whole faces a mix of risks and opportunities.

The development of the synthetic biology track has brought new product and growth opportunities for brands, with key takeaways summarized below:

1. Consumer and policy trends: China has relaxed regulatory approvals for synthetic biology-derived ingredients, while ongoing consumption upgrading has driven rising consumer demand for green, functional ingredients. The food and alternative protein segment saw explosive growth in 2025, with the number of financing events doubling. Functional ingredients such as HMOs have already gained recognition from industrial capital, making them suitable for brands looking to expand into new categories.

2. Product R&D opportunities: Synthetic biology enables production of greener, more precise ingredients, and can theoretically replace all petrochemical-derived feedstocks, aligning with the green transition trend currently prioritized by brands. It can be applied across multiple core brand sectors including food, cosmetics and materials.

3. Key risks to note: Consumer acceptance of "synbio-made" products still needs to be cultivated, resulting in high market education costs. Brands looking to roll out new ingredients should first build consumer awareness, and prioritize ingredients that have already passed regulatory approval to reduce risk.

China's synthetic biology track is currently in an early stage of development, bringing new opportunities and risks for upstream and downstream sellers along the industrial chain, with key insights below:

1. Growth opportunities to capture: Food/alternative protein and functional ingredients are the fastest-growing segments in 2025, driven by both policy liberalization and consumption upgrading. Niche categories such as HMOs and ergothioneine have seen a flurry of financing activity. The Yangtze River Delta has formed an industrial cluster for commercialized synbio projects, and Hefei has replicated its successful new energy industry model by launching a support policy combining state-owned capital lead investment and industrial introduction, unlocking abundant policy dividends.

2. Key risk warnings: The vast majority of projects are still at Series B or earlier stages. The failure rate for scale-up from lab-gram production to ton-level mass production is high, and commercialization cycles stretch 5 to 10 years, which mismatches the fund life cycle of venture capital, leading to high uncertainty for follow-on financing. Most platform companies have pursued expansion into multiple scenarios without deeply penetrating any single market.

3. Recommended opportunity areas: Sellers can prioritize partnering with projects that have already secured state-backed capital support and clear mass production roadmaps. The integration of AI and synthetic biology currently has large unmet demand, leaving substantial room for growth for related supporting products and services.

The growth of synthetic biology has opened up new business opportunities and transformation directions for traditional manufacturers, with key insights below:

1. Product manufacturing and design demand: Market demand for green synthetic biology-derived products is currently strong, including biodegradable bio-based materials that replace petroleum-based products, synthetic functional food ingredients, and pharmaceutical APIs. These align with the policy direction of green transition and have enormous market potential.

2. Accessible business opportunities: Most domestic synthetic biology startups are currently in the pilot or mass production ramp-up stage, and lack access to mature manufacturing capacity. Traditional factories with existing capabilities in fermentation, product separation and purification, and large-scale production can enter into capacity cooperation partnerships with startups to capture new business growth.

3. Transformation takeaways: Synthetic biology is a nationally recognized strategic emerging industry, and multiple local governments have introduced dedicated support policies. Traditional factories can seize this policy opportunity, partner with local state-owned capital and industrial parks, proactively lay out green capacity, and upgrade through partnerships with synbio projects. This allows them to meet regulatory requirements such as plastic restrictions and open up new growth curves.

China's synthetic biology industry is in an early-stage validation phase, bringing clear market opportunities for relevant service providers, with key insights below:

1. Industry development trends: The domestic track has accumulated 21.8 billion yuan in total financing, and saw a clear recovery in 2025. The global market has a CAGR exceeding 21%, with abundant long-term growth room. State-owned capital has already begun systematic entry into the sector, providing long-term stable capital support, and multiple niche segments are growing rapidly.

2. Core customer pain points: Synthetic biology startups commonly face a "valley of death" between lab R&D and mass production, with multiple bottlenecks in strain stability, process scale-up, and separation and purification leading to high scale-up failure rates. Most early-stage startups lack experience in regulatory approval, as regulatory pathways vary widely across different segments, and they also lack access to industrial resource connection channels.

3. Targeted solution entry points: Service providers can develop tailored offerings including pilot process scale-up services, regulatory consulting, and AI-assisted strain design. They can also connect startups with industrial capital and industrial park resources to provide end-to-end commercialization support. The AI-synthetic biology integration segment has large unmet demand and substantial growth potential.

The rapid growth of the synthetic biology industry has brought new opportunities for industrial platforms, with key takeaways summarized below:

1. Core industry demand for platforms: Synthetic biology startups operate across a wide range of segments, requiring end-to-end supporting services from R&D and pilot testing to mass production. Different segments require connections with different downstream industrial resources: for example, food-focused startups need connections with consumer brands, pharma-focused startups need pharmaceutical partners, and material startups need connections with chemical companies. This requires platforms to build comprehensive resource connection networks.

2. Proven operational models to reference: Hangzhou has developed strong agglomeration effects through its local synthetic biology industrial park, leveraging the Yangtze River Delta's existing industrial base in biopharmaceuticals, chemicals and manufacturing to attract a large number of startup projects. Hefei has adopted a "state capital lead investment + industrial introduction" model, replicating its successful experience in the new energy sector, and has already attracted multiple high-quality projects to land.

3. Key points for investment promotion and risk mitigation: Platforms can prioritize recruiting projects in the food/alternative protein segment, which boomed in 2025, and partner with state-owned capital to access policy support. At the same time, it is important to note that the industry as a whole remains early-stage, so platforms should avoid concept-only projects without commercialization capabilities, and prioritize projects with clear technology pipelines and active progress toward mass production, while providing adequate incubation periods for early-stage projects.

Based on 301 financing records from IT桔子, this article provides a full overview of China's synthetic biology industry with high value for industrial research, with core content below:

1. Latest industry trends: Domestic synthetic biology financing experienced a boom from 2021 to 2022, a contraction from 2023 to 2024, and entered a recovery phase in 2025. Capital allocation has shifted from the early concentrated hype for platform companies to niche application segments, with food/alternative protein emerging as a standout growth area. State-owned capital has begun systematic entry into the sector, while participation from industrial capital and corporate CVCs remains low. The integration of AI and synthetic biology has emerged as a new growth direction. Geographically, the Yangtze River Delta leads the industry, and Hefei has emerged as a new industrial hot spot.

2. New emerging industry problems: The industry as a whole faces a widespread "valley of death" between lab R&D and mass production, with 5 to 10-year commercialization cycles that mismatch the fund life of VC funds, creating heavy exit pressure. Currently only 5 companies have reached Series C or beyond, and nearly 80% of all projects remain at Series A or earlier. Capital is no longer bullish on the multi-scene expansion commercialization path adopted by most platform companies.

3. Implications for policy research: Multiple local governments have already introduced dedicated support policies. Going forward, further improvements are needed in public infrastructure such as pilot test platforms, incentives to encourage industrial capital entry, and clearer categorized regulation for synthetic biology products. These steps will reduce commercialization risk for the industry and help the sector move from concept to full-scale commercialization.